- Home
- PETZ vs LNAI Comparison
PETZ vs LNAI Comparison
Compare PETZ & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | LNAI |
|---|---|---|
| Founded | 2002 | N/A |
| Country | China | United States |
| Employees | N/A | 29 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 11.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PETZ | LNAI |
|---|---|---|
| Price | $1.42 | $2.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 712.8K | 430.2K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.15 |
| 52 Week High | $1.68 | $3.38 |
Technical Indicators
Market Signals| Indicator | PETZ | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 80.07 | 64.06 |
| Support Level | $0.98 | $0.93 |
| Resistance Level | $1.68 | $3.38 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 71.43 | 66.24 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.